Vmn2r46 Inhibitors
Vmn2r46 can act through various molecular pathways to reduce the protein's activity. Olmutinib, gefitinib, and erlotinib target and inhibit the EGFR signaling pathway. By impeding EGFR, these inhibitors can diminish the downstream signaling that is necessary for the activity of Vmn2r46. Similarly, lapatinib acts as a dual inhibitor on both EGFR and HER2/neu receptors, potentially compromising the signaling required for Vmn2r46. Sorafenib and sunitinib, which target multiple tyrosine protein kinases such as VEGFR, PDGFR, and the Raf kinases, can also decrease the signaling environment that Vmn2r46 relies on for its function. Vandetanib takes a similar approach by inhibiting key tyrosine kinases involved in cell signaling, including VEGFR, EGFR, and RET.
Dactolisib and everolimus, both mTOR inhibitors, disrupt a central regulatory kinase in cell growth and proliferation, thereby reducing the downstream effects on cellular processes that could be essential for Vmn2r46 activity. Temsirolimus, another mTOR inhibitor, follows the same inhibitory pathway and can impair the cell signaling that may contribute to the role of Vmn2r46. Trametinib, a MEK inhibitor, obstructs the MAPK/ERK pathway, which is important for cell proliferation and differentiation; this obstruction can suppress the activity of Vmn2r46. Lastly, palbociclib, a CDK4/6 inhibitor, disrupts the cell cycle, which may lead to a reduction in Vmn2r46 activity by decelerating cell cycle progression where Vmn2r46 might be active. Taken together, these chemical inhibitors utilize different mechanisms to downregulate the activity of Vmn2r46, each targeting distinct pathways that are likely involved in the regulation and function of the protein.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $211.00 | 8 | |
Dactolisib inhibits the PI3K/AKT/mTOR signaling pathway, a key pathway for cell growth and survival. As Vmn2r46 is implicated in cellular signaling, inhibiting this pathway could suppress the functional activity of Vmn2r46 by reducing the signaling required for its activity. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor that impairs the MAPK/ERK pathway, which is crucial for cell proliferation and differentiation. By inhibiting this pathway, Trametinib could suppress the activity of Vmn2r46, as MAPK/ERK signaling may be necessary for Vmn2r46's functional role. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a CDK4/6 inhibitor that disrupts the cell cycle. Since Vmn2r46 is involved in cellular processes, inhibiting CDK4/6 could result in a reduction of Vmn2r46 activity due to a decrease in cell cycle progression where Vmn2r46 might be active. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib targets multiple tyrosine protein kinases, such as VEGFR and PDGFR, and the Raf kinases involved in cell signaling. Inhibiting these kinases could diminish the cellular signaling environment necessary for Vmn2r46 activity. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor, affecting pathways like VEGFR and PDGFR. Disruption of these pathways can lead to decreased signaling required for the proper function of Vmn2r46, resulting in its inhibition. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib selectively inhibits the EGFR tyrosine kinase, which could be upstream of Vmn2r46. By inhibiting EGFR, the signal transduction potentially required for Vmn2r46 activity would be impeded, leading to its functional inhibition. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor acting on both EGFR and HER2/neu. By inhibiting these receptors, the necessary signaling for Vmn2r46 activity could be compromised, resulting in the inhibition of Vmn2r46. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib inhibits VEGFR, EGFR, and RET tyrosine kinases, which are involved in angiogenesis and cell proliferation. By inhibiting these kinases, the signaling required for Vmn2r46 function could be reduced, leading to inhibition of Vmn2r46. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus is an mTOR inhibitor that disrupts a central regulatory kinase in cell growth and proliferation. By inhibiting mTOR, the downstream effects on cellular processes that could be essential for Vmn2r46 activity are reduced, leading to its inhibition. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib inhibits EGFR tyrosine kinase, which could have an upstream effect on Vmn2r46. The inhibition of EGFR could lead to a decrease in the necessary signaling for Vmn2r46 function, thus inhibiting its activity. | ||||||